Rep. Gilbert Ray Cisneros, Jr. Buys Veracyte, Inc. (NASDAQ:VCYT) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Veracyte, Inc. (NASDAQ:VCYT). In a filing disclosed on July 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Veracyte stock on June 16th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

Veracyte Stock Down 2.9%

NASDAQ:VCYT traded down $0.71 during midday trading on Friday, hitting $23.51. The stock had a trading volume of 1,613,012 shares, compared to its average volume of 921,085. Veracyte, Inc. has a one year low of $19.73 and a one year high of $47.32. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 57.34 and a beta of 2.07. The stock has a 50-day moving average of $27.15 and a 200 day moving average of $32.81.

Wall Street Analyst Weigh In

VCYT has been the subject of a number of recent analyst reports. Needham & Company LLC lowered their price objective on Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. UBS Group reduced their target price on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Stephens reiterated an "overweight" rating and set a $45.00 price objective on shares of Veracyte in a research note on Wednesday, March 26th. Guggenheim reduced their price objective on Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Finally, Wall Street Zen lowered Veracyte from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.90.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its holdings in Veracyte by 49.7% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock valued at $28,000 after buying an additional 237 shares during the last quarter. Arizona State Retirement System increased its holdings in Veracyte by 1.2% in the fourth quarter. Arizona State Retirement System now owns 22,276 shares of the biotechnology company's stock valued at $882,000 after buying an additional 264 shares during the last quarter. Synovus Financial Corp increased its holdings in Veracyte by 1.2% in the fourth quarter. Synovus Financial Corp now owns 23,132 shares of the biotechnology company's stock valued at $916,000 after buying an additional 267 shares during the last quarter. HighTower Advisors LLC increased its holdings in Veracyte by 1.9% in the fourth quarter. HighTower Advisors LLC now owns 16,630 shares of the biotechnology company's stock valued at $659,000 after buying an additional 305 shares during the last quarter. Finally, Xponance Inc. increased its holdings in Veracyte by 5.7% in the first quarter. Xponance Inc. now owns 6,860 shares of the biotechnology company's stock valued at $203,000 after buying an additional 370 shares during the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.